Skip to main content
. 2020 Dec 8;6:140. doi: 10.1038/s41420-020-00378-9

Fig. 4. FN-EDA promoted angiogenesis through Integrins.

Fig. 4

A, B Tube formation assay of HUVECs and HSECs treated with Irigenin or Resatorvid (5 μM) along with FN-EDA (40 μg/ml) for 6 h (n = 3). (Data are shown as mean ± SEM; HUVEC: Irigenin versus Ctrl: **P < 0.001; Resatorvid versus Ctrl: ns. HSEC, Irigenin versus Ctrl: **P < 0.001; Resatorvid versus Ctrl: *P < 0.01; scale bar = 100 μm.) C, D Migration assay of HUVECs and HSECs treated with Irigenin or Resatorvid (5 μM) along with FN-EDA (40 μg/ml) for 24 h (n = 3). (Data are shown as mean ± SEM; HUVEC, Irigenin versus Ctrl: **P < 0.001; Resatorvid versus Ctrl: ns. HSEC, Irigenin versus Ctrl: **P < 0.001; Resatorvid versus Ctrl: ns; scale bar = 100 μm.) E, F Immunoblot result of HUVECs and HSECs treated with Irigenin or Resatorvid (5 μM) along with FN-EDA (40 μg/ml) for 6 h (n = 3). (Data are shown as mean ± SEM; HUVEC: Irigenin versus Ctrl: *P < 0.01; Restorvid versus Ctrl: ns; HSEC: Irigenin versus Ctrl: **P < 0.001; Restorvid versus Ctrl: ns.) G, H Tube formation assay of HUVECs and HSECs pretreated with varies of integrin neutralizing antibodies anti-α9, anti-α4, anti-β1 or IgG (40 μg/ml) 20 minutes before rEDA (40 μg/ml) stimulation for 6 h (n = 3). (Data are shown as mean ± SEM; HUVEC: anti-α9 versus Ctrl: ns; anti-α4 versus Ctrl: **P < 0.001; anti-β1 versus Ctrl: ***P < 0.0001. HSEC, anti-α9 versus Ctrl: *P < 0.01; anti-α4 versus Ctrl: *P < 0.01; anti-β1 versus Ctrl: ***P < 0.0001; scale bar = 100 μm.) I, J Migration assay of HUVECs and HSECs treated with varies of integrin neutralizing antibodies anti-α9, anti-α4, anti-β1 or mouse IgG (40 μg/ml) 20 minutes before rEDA (40 μg/ml) stimulation for 24 h (n = 3). (Data are shown as mean ± SEM; HUVEC, anti-α9 versus Ctrl: ***P < 0.0001; anti-α4 versus Ctrl: ns; anti-β1 versus Ctrl: ***P < 0.0001. HSEC, anti-α9 versus Ctrl: **P < 0.001; anti-α4 versus Ctrl: ns; anti-β1 versus Ctrl: *P < 0.01; scale bar = 100 μm.) K Immunoblot result of HUVECs pretreated with varies of integrin neutralizing antibodies anti-α9, anti-α4, anti-β1 or IgG (40 μg/ml) 20 min before rEDA (40 μg/ml) stimulation for 6 h (n = 3). (Data are shown as mean ± SEM; HUVEC, anti-α9 versus Ctrl: *P < 0.01; anti-α4 versus Ctrl: **P < 0.001; anti-β1 versus Ctrl: **P < 0.001).